Sustained and rebound effect of repeated low-level red-light therapy on myopia control: A 2-year post-trial follow-up study
Xiong R, Zhu Z, Jiang Y, Kong X, Zhang J, Wang W, Kiburg K, Yuan Y, Chen Y, Zhang S, Xuan M, Zeng J, Morgan IG, He M
Clinical & experimental ophthalmology · 115 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- University of Melbourne
- Government
- National Natural Science Foundation of China
- University or hospital
- State Key Laboratory of Ophthalmology
- Authors
- At least one author declares a financial tie to industry
- Grants
- National Natural Science Foundation of China (81271037); State Key Laboratory of Ophthalmology (303060202400362); National Natural Science Foundation of China (81420108008)
Based on 3 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2022-08-25 · Clin Exp Ophthalmol · vol. 50 · issue 9 · pp. 1013–1024
- Publisher
- Wiley
- Cited
- 133 citations · more than 100% of similar papers · 15.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 26 works
- Access
- Open access (hybrid journal) · CC-BY-NC-ND
- Research areas
- Ophthalmology and Visual Impairment Studies · Retinopathy of Prematurity Studies · Laser Applications in Dentistry and Medicine
- Keywords
- Medicine, Randomized controlled trial, Ophthalmology, Light therapy, Repeated measures design, Surgery, Internal medicine, Circadian rhythm
- MeSH
- humans, myopia, disease progression, refraction, ocular, phototherapy, follow-up studies, eyeglasses, child, axial length, eye
14 authors
From CN, AU
- Ruilin XiongSun Yat-sen University
- Zhuoting ZhuSun Yat-sen University; The University of Melbourne; Centre for Eye Research Australia
- Yu JiangSun Yat-sen University
- Xiangbin KongFoshan Maternity and Child Health Care Hospital; Southern Medical University
- Jian ZhangSun Yat-sen University
- Wei WangSun Yat-sen University
Abstract
Background
To evaluate the long-term efficacy and safety of continued repeated low-level red-light (RLRL) therapy on myopia control over 2 years, and the potential rebound effect after treatment cessation.
Methods
The Chinese myopic children who originally completed the one-year randomised controlled trial were enrolled. Children continued RLRL-therapy were defined as RLRL-RLRL group, while those who stopped and switched to single-vision spectacle (SVS) in the second year were RLRL-SVS group. Likewise, those who continued to merely wear SVS or received additional RLRL-therapy were SVS-SVS and SVS-RLRL groups, respectively. RLRL-therapy was provided by an at-home desktop light device emitting red-light of 650 nm and was administered for 3 min at a time, twice a day and 5 days per week. Changes in axial length (AL) and cycloplegic spherical equivalence refraction (SER) were measured.
Results
Among the 199 children who were eligible, 138 (69.3%) children attended the examination and 114 (57.3%) were analysed (SVS-SVS: n = 41; SVS-RLRL: n = 10; RLRL-SVS: n = 52; RLRL-RLRL: n = 11). The baseline characteristics were balanced among four groups. In the second year, the mean changes in AL were 0.28 ± 0.14 mm, 0.05 ± 0.24 mm, 0.42 ± 0.20 mm and 0.12 ± 0.16 mm in SVS-SVS, SVS-RLRL, RLRL-SVS and RLRL-RLRL group, respectively (p < 0.001). The respective mean SER changes were -0.54 ± 0.39D, -0.09 ± 0.55D, -0.91 ± 0.48D, and -0.20 ± 0.56D (p < 0.001). Over the 2-year period, axial elongation and SER progression were smallest in RLRL-RLRL group (AL: 0.16 ± 0.37 mm; SER: -0.31 ± 0.79D), followed by SVS-RLRL (AL: 0.44 ± 0.37 mm; SER: -0.96 ± 0.70D), RLRL-SVS (AL: 0.50 ± 0.28 mm; SER: -1.07 ± 0.69D) and SVS-SVS group (AL: 0.64 ± 0.29 mm; SER: -1.24 ± 0.63D). No self-reported adverse events, functional or structural damages were noted.
Conclusions
Continued RLRL therapy sustained promising efficacy and safety in slowing myopia progression over 2 years. A modest rebound effect was noted after treatment cessation.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.